NCT05293808 (DIABE-ASACS) is a Phase 4 clinical trial of aspirin 100 mg bis in die in Acute Coronary Syndrome, sponsored by Federico II University.

Who is sponsoring NCT05293808?

NCT05293808 is sponsored by Federico II University.

What drugs are being tested in NCT05293808?

Interventions in NCT05293808: aspirin 100 mg bis in die, aspririn 200 mg once daily, aspirin 100 mg once daily.

What condition does NCT05293808 study?

NCT05293808 studies Acute Coronary Syndrome, Diabetes Mellitus.

Is NCT05293808 still recruiting?

NCT05293808 is currently completed. Last updated 23 February 2024.

Last reviewed 2024-02-23 · How we verify

NCT05293808: DIABE-ASACS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Platelet Aggregation in Diabetic Patients With Acute Coronary Syndrome Treated With Different Doses of Aspirin

Completed Phase 4 Last updated 23 February 2024

What this trial tests

Phase 4 trial testing aspirin 100 mg bis in die in Acute Coronary Syndrome in 60 participants. Completed in 1 January 2016.

Timeline

1 May 2014

Primary endpoint
1 October 2014

1 January 2016

Quick facts

Lead sponsor	Federico II University
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	60
Start date	1 May 2014
Primary completion	1 October 2014
Estimated completion	1 January 2016
Sites	1 location across Italy

Drugs / interventions tested

aspirin 100 mg bis in die — full drug profile →
aspririn 200 mg once daily — full drug profile →
aspirin 100 mg once daily — full drug profile →

Conditions studied

Acute Coronary Syndrome — all drugs for Acute Coronary Syndrome →
Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

Federico II University

Who can join

Adults 40 to 80, any sex, with Acute Coronary Syndrome or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Coronary Syndrome

Currently open trials in the same condition.

NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07230847 — A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug- · NA · recruiting
NCT07032389 — A Polypill for Acute Coronary Syndrome · Phase 2 · recruiting
NCT07102628 — Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronar · Phase 3 · recruiting
NCT06416813 — Preventive Intervention Value of DCB in Vulnerable Coronary Atherosclerotic Plaques · NA · active not recruiting

Other Federico II University trials

Trials by the same sponsor.

NCT07437690 — Fall Prevention in Older Adults in an Italian Cohort · not yet recruiting
NCT07282132 — Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter · not yet recruiting
NCT07280286 — Incidence of Intrauterine Adhesions After Myomectomy With Intrauterine Anti-Adhesion Gel · NA · not yet recruiting
NCT07374861 — Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Bempedoic Acid in Italy · recruiting
NCT07314684 — GLP1-RAs Effects on Inflammatory and Endothelial Biomarkers in T2DM · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05293808 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Federico II University
Last refreshed: 23 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05293808.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing